Company / R&D Expense
MEDICINOVA INC R&D Expense History
FY2011-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest R&D Expense
$6.7M
FY2025
5-year range
$5.3M / $8.7M
FY2021-FY2025
Trend
+26.4%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Declined from $9M to $7M over the past 2 years.
Based on SEC 10-K filings.
$7M in FY2025 with a 3-year CAGR of -8.3%.
Declined from $9M to $7M over the past 2 years.
R&D Expense over time
Growth rates
- 3-Year CAGR
- -8.3%
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- 3-year CAGR of -8.3%, indicating a declining trend.
- In FY2025, r&d expense increased 26.4% year-over-year.
- Peak r&d expense was recorded in FY2023.
- Lowest r&d expense in the period was in FY2014.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -4.27 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | R&D ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $6.7M | +26.4% |
| FY2024 | $5.3M | -39.1% |
| FY2023 | $8.7M | +0.0% |
| FY2022 | $8.7M | +7.4% |
| FY2021 | $8.1M | +179.3% |
| FY2014 | $2.9M | -35.6% |
| FY2013 | $4.5M | -42.2% |
| FY2012 | $7.8M | +0.0% |
| FY2011 | $7.8M | - |
As of FY2025 · SEC 10-K · Updated Jun 28, 2026